StockTipsArenaBeta

BUY Epigral Limited — Emkay Global

BUYEpigral Limited
Epigral share price target & all analyst calls

byEmkay GlobalHorizon: NA (inferred 1 year)6 May 2025via Institutional / Brokerage Research

Entry₹1,779.6Inferred
Target₹2,450
Total upside +37.67% (call closed)
Stop lossNot given
At expiry₹1,3646 May 2026, 3:30 pm
Expired-23.35%
Follow Emkay Global for new calls(64% target hit, 377 closed calls)Get alertsWatch EPIGRAL for new buy/sell callsGet alertsSee 276 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 23 Oct, 11:23 pm IST
2 supporting1 neutral0 opposing
Supports the BUY call (2)

Epigral Limited reported record Q4FY26 revenue of Rs 736 Cr, up 17% YoY, and proposed a final dividend of Rs 5 per share. The company also announced strategic updates including capex plans for CPVC an

NSE · Press Release·2 May · 3d ago

(opens in new tab)

Epigral Limited's Board of Directors approved the audited financial results for the fourth quarter and year ended March 31, 2026. The company also recommended a final dividend of Rs. 5.00 per equity s

NSE · Outcome of Board Meeting·2 May · 3d ago

(opens in new tab)
Neutral / worth noting (1)

Approved Audited Financial Results (Standalone & Consolidated) for the Fourth Quarter and Year ended on 31st March, 2026 and Recommended Final dividend of Rs. 5.00 (50%) per Equity Share ....

BSE · Board Meeting·2 May · 3d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Epigral

All analyst calls on Epigral

More from Emkay Global

Every call and its outcome